IRB Process Streamlining Expected In 21st Century Cures Bill
A move toward centralized institutional review board approval of study protocols could reduce clinical trial delays; House Energy and Commerce Committee also is looking at optimizing use of real-world data in the post-market setting.
You may also be interested in...
Simplified and speedier drug approval process is focus for Reps. Upton and DeGette’s upcoming legislation – but getting there may mean more congressional micromanaging over FDA’s drug approval standards.
Next iteration of user fee legislation could include reducing amount of data sponsors must collect; 21st Century Cures initiative represents ‘dry run’ that could smooth agreement, Pfizer rep says.
New Senate GOP majority suggests Rep. Upton's initiatives might find greater support in that chamber.